<DOC>
	<DOCNO>NCT00106379</DOCNO>
	<brief_summary>The purpose study provide long-term clinical safety efficacy data tenofovir disoproxil fumarate emtricitabine HIV-infected patient experience various degree renal impairment .</brief_summary>
	<brief_title>Tenofovir DF ( Disoproxil Fumarate ) Combination With Emtricitabine HIV-1 Patients</brief_title>
	<detailed_description>The primary objective study follow : - To evaluate safety tolerability tenofovir follow administration tenofovir disoproxil fumarate 300 mg 48 week HIV-infected patient experience various degree renal impairment . The secondary objective study follow : - To evaluate safety tolerability emtricitabine follow administration emtricitabine 200 mg 48 week HIV-infected patient experience various degree renal impairment . - To evaluate efficacy tenofovir disoproxil fumarate combination emtricitabine renally-impaired HIV-infected patient . - To evaluate pharmacokinetics tenofovir emtricitabine renally-impaired HIV-infected patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible participation study . HIV1 infection Either antiretroviral therapynaive require antiretroviral treatment HIV1 RNA great 400 copies/mL antiretroviral therapyexperienced stable antiretroviral regimen least 3 mo . HIV1 RNA less equal 50 copies/mL screening . No active opportunistic infection within 45 day prior baseline . Able understand sign inform consent form comply study . Stable renal impairment within four define group least 3 mos. , base creatinine clearance ( CockcroftGault method ) . Patients meet follow enrol study . Women pregnant breastfeed Fanconi syndrome multiple myeloma , tertiary hyperparathyroidism , malignancy ( exception basocellular carcinoma ) myeloproliferative disorder . Women childbearing potential unwilling use effective contraceptive method study Contraindications tenofovir DF , emtricitabine efavirenz Undergoing treatment tuberculosis Using atazanavir Prior history mutation M184V , K65R T69 insertion Zscore prebaseline DEXA scan less 2.5 The following laboratory value within 30 day prior study entry : *absolute neutrophil count ( ANC ) less 750/mm3 , *hemoglobin le 9.0 g/dL , *platelet count less 50,000/mm3 , *AST ( SGOT ) ALT ( SGPT ) less 5 x ULN *CD4 cell count less 100/mm3 . Use nephrotoxic agent competitor renal excretion , include aminoglycoside antibiotic , intravenous amphotericin B , cidofovir , cisplatin , foscarnet , intravenous pentamidine , probenecid agent significant nephrotoxic potential Clinically significant cardiac , pulmonary gastrointestinal disorder Alcohol drug abuse could hinder compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>